In this episode of The Growth Blueprint, Senior Partners Christian Schuler and Robert Dumitrescu discuss how global pharma and biotech are being transformed by Most Favored Nation pricing, Europe’s new Joint Clinical Assessment framework, and the growing focus on equitable access. Together they explore how these trends affect global pricing, evidence generation, launch strategy, and BD&L. Discover practical steps companies can take to adapt portfolios, access strategies, and deal structures for 2026 and beyond. For more resources, please visit: https://www.simon-kucher.com/